Background: Various publications have noted increases in dopamine, specifically in the mesolimbic region of the brain, to have a direct correlation to psychotic-like symptoms. Venlafaxine, a first-line medication for depression, inhibits the reuptake of both serotonin and norepinephrine. Additionally, venlafaxine weakly inhibits the reuptake of dopamine. Phentermine/topiramate (Qsymia®), specifically the phentermine component, functions by blocking the dopamine and norepinephrine transporter, similar to amphetamine.
Case Report: A 40-year-old Hispanic woman was admitted to the inpatient mental health unit based on reports of delusional thinking and several attempts of self-harm. Past medical history was significant for major depressive disorder, posttraumatic stress disorder, anxiety, irritable bowel syndrome, and migraines. The patient was started on venlafaxine (75 mg extended-release by mouth once daily) for depression approximately 1 month prior to admission. Furthermore, the patient was restarted on a previously prescribed medication, oral phentermine/topiramate for weight loss, in combination with venlafaxine, approximately 1 week prior to the bizarre behavior. The patient denied any psychosis or changes in behavior when medications were taken individually prior to the combination. The patient was treated with lurasidone (40 mg by mouth daily) with resolution of psychosis.
Discussion: A PubMed search revealed no current literature or case reports on psychosis induced by the combination of venlafaxine and phentermine/topiramate. Individual case reports of psychosis in patients on venlafaxine alone and the phentermine component of phentermine/topiramate alone have been reported.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007738 | PMC |
| http://dx.doi.org/10.9740/mhc.2018.03.095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Significance of Psychological Support in Managing Depression in Parkinson's Disease: Combining Venlafaxine with Pramipexole and Psychological Care.
Actas Esp Psiquiatr
January 2025
Neurology Department, Geriatric Hospital of Hainan, 571100 Haikou, Hainan, China.
Background: Depression is a common comorbidity in patients with Parkinson's disease (PD) and can significantly impact their overall well-being. The combination of venlafaxine and pramipexole is a standard treatment approach for depression in PD. However, the effects of incorporating psychological care into the treatment regimen remain unclear.
View Article and Find Full Text PDFFirst Episode Psychosis in a Teen with Narcolepsy and Cataplexy.
Psychopharmacol Bull
January 2025
Abhishek Reddy, MD, Assistant Professor, Child and Adolescent Psychiatry, Sleep Medicine, Department of Psychiatry, Virginia Tech Carilion School of Medicine, Roanoke, VA, United States.
Article Synopsis
- Narcolepsy with cataplexy (NT1) is a rare sleep disorder that can be linked to early-onset psychosis, particularly in kids and teens.
- After excluding other medical issues, an adolescent girl with NT1 was initially diagnosed with a brief psychotic episode and treated with Risperidone.
- Her symptoms improved significantly after switching to Chlorpromazine, marking one of the first successful uses of this drug for managing first-episode psychosis in a patient with NT1.
Ansofaxine suppressed NSCLC progression by increasing sensitization to combination immunotherapy.
Int Immunopharmacol
January 2025
School of Medicine, Guizhou University, Guiyang 550025, China; NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China. Electronic address:
Introduction: Depression negatively impacts the prognosis of various cancers, including lung cancer, by influencing antitumor immune responses and impairing immune cell function. Antidepressants may modulate the tumor immune microenvironment, enhancing immunotherapy efficacy. However, the specific mechanisms remain unclear.
View Article and Find Full Text PDFRisk of congenital anomalies associated with psychotropic medications: a review of neonatal reports in the FDA adverse event reporting System (FAERS).
Arch Womens Ment Health
December 2024
College of Pharmacy, Jinan University, Guangzhou, Guangdong, China.
Purpose: This study investigates the potential association between commonly prescribed psychotropic medications, such as Atypical Antipsychotics (AAs), Selective Serotonin Reuptake Inhibitors (SSRIs), and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), and congenital anomalies in newborns. The analysis uses data from the Food and Drug Administration Adverse Event Reporting System (FAERS).
Methods: Spontaneously reported cases of congenital anomalies in newborns (under 28 days old) were extracted from the FAERS database, covering January 2004 to June 2023.
Sleep deprivation activated AMPK/FOXO3a signaling mediates pineal autophagy impairment to reduce melatonin secretion in CUMS + SD rats leading to depression combined with insomnia.
Neurosci Lett
December 2024
Basic Medical College, Guangxi University of Chinese Medicine, Nanning 530200, China.
This study established an animal model of comorbid depression and insomnia by combining chronic unpredictable mild stress (CUMS) with sleep deprivation (SD). The pathogenesis of comorbid depression and insomnia may be associated with impaired AMPK/FOXO3a signaling, which mediates autophagy inhibition, leading to decreased pineal melatonin secretion. The findings revealed that CUMS + SD rats exhibited more pronounced depression-like behaviors, sleep disorders, increased central oxidative stress, and exacerbated neuroinflammation, accompanied by reduced levels of 5-hydroxytryptophan (5-HT) and melatonin in the pineal gland.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!